Who is sponsoring NCT00405067?

NCT00405067 is sponsored by Aegerion Pharmaceuticals, Inc..

What condition does NCT00405067 study?

NCT00405067 studies Hypercholesterolemia.

What drugs are being tested in NCT00405067?

Interventions: BMS-201038 (AEGR-733), Ezetimibe.

What is the status of NCT00405067?

NCT00405067 is currently COMPLETED.

Last reviewed 2014-01-15 · How we verify

A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

NCT00405067 Phase 2 COMPLETED Results posted

The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.

Details

Lead sponsor	Aegerion Pharmaceuticals, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2006-05
Completion	2007-01

Conditions

Hypercholesterolemia

Interventions

BMS-201038 (AEGR-733)
Ezetimibe

Primary outcomes

Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments — Baseline and 12 weeks of treatment

Countries

United States